AADC Gene Therapy Dosing and Frameless Brain Delivery in Children
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for AADC deficiency, particularly in pediatric patients, lack data on the safety and efficacy of high doses, are not feasible for pediatric subjects due to the use of cumbersome skull-fixed head frames, and do not address AADC gene therapy-induced dyskinesia, with limited effectiveness and immune system interference.
Innovation Solution
A method involving frameless stereotaxy to deliver a pharmaceutical formulation comprising an rAAV2-hAADC vector to the brain at tailored doses, optionally with dopamine-antagonists, to treat AADC deficiency, using a WT AAV2 capsid and recombinant DNA DDC gene insert, and incorporating empty capsids to enhance transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If high doses of rAAV2-hAADC vector are administered to pediatric patients, then treatment efficacy is improved, but safety data is insufficient
Solution Approach 1:
The patent applies parameter changes by establishing dose ranges (1.8×10^11 to 2.4×10^11 vg) based on body weight and age, transitioning from fixed low doses to customized high doses. This allows optimization of treatment efficacy while maintaining safety through systematic parameter adjustment rather than arbitrary dosing.
Solution Approach 2:
The patent incorporates feedback mechanisms through monitoring of AADC enzyme activity, neurotransmitter levels, and clinical symptoms during and after treatment. This feedback loop enables real-time assessment of efficacy and safety, allowing dose optimization based on individual patient response while accumulating reliability data.
2Measurement precision
If skull-fixed head frame stereotaxy is used for gene therapy delivery, then delivery precision is improved, but feasibility for pediatric subjects deteriorates
Solution Approach 1:
The patent extracts the essential functionality of stereotactic delivery precision while removing the cumbersome skull-fixed head frame. This allows the use of frameless stereotaxy with image-guided navigation systems that provide sufficient precision for brain target delivery without the operational complexities and discomfort of traditional head frames in pediatric patients.
Solution Approach 2:
The patent replaces the mechanical skull-fixed head frame system with image-guided navigation and frameless stereotaxy. This substitution maintains delivery precision through computational localization while eliminating the mechanical constraints and operational difficulties associated with securing head frames to pediatric skulls.
3Object-affected harmful factors
If conventional drug therapy is used for AADC deficiency, then some symptom relief is achieved, but overall treatment effectiveness deteriorates
Solution Approach 1:
The patent introduces rAAV2-hAADC vectors as an intermediary that directly delivers functional AADC enzyme to target brain cells. This bypasses the limitations of conventional drug therapy that only provides temporary symptom relief, enabling sustained treatment effectiveness through genetic modification and enzyme replacement at the cellular level.
Solution Approach 2:
The patent performs preliminary action by administering gene therapy vectors before severe complications occur, aiming to restore AADC enzyme function proactively. This preventive approach differs from conventional therapy that reacts to symptoms, potentially improving overall treatment effectiveness by addressing the root cause rather than just managing manifestations.
4Reliability
If immune system responds to AAV vector delivery, then vector neutralization occurs, but transduction efficiency deteriorates
Solution Approach 1:
The patent converts the harmful immune response that neutralizes vectors into a beneficial effect by using empty capsids as decoys. These empty capsids engage immune cells and neutralizing antibodies, protecting the functional vectors from immune destruction. This transforms the harmful immune activity into a protective mechanism that enhances transduction efficiency.
Solution Approach 2:
The patent introduces empty capsids as an intermediary substance that mediates between the immune system and functional vectors. These empty capsids act as sacrificial decoys that absorb immune attention, allowing the functional vectors to evade immune detection and maintain transduction efficiency despite the presence of neutralizing antibodies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides higher doses tailored to pediatric patients, reduces immune interference, prevents dyskinesia, and enhances gene therapy transduction, offering greater precision and safety without the need for skull-fixed frames.
Implementation Method 1
recombinant adeno-associated virus (rAAV) type 2 vector-mediated delivery of the human AADC gene
Implementation Method 2
AADC is an enzyme reported in the literature as responsible for the final step in the synthesis of neurotransmitters dopamine and serotonin
Data Source
AI summary
The present invention is directed to compositions and methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency. This invention includes a method of treating AADC deficiency in a pediatric subject, comprising the steps of: (a) providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, (b) stereotactically delivering the pharmaceutical formulation to at least one target site in the brain of the subject in a dose of an amount at least about 1.8×1011 vg; wherein delivering the pharmaceutical formulation to the brain is optionally by frameless stereotaxy, and optionally wherein the dose is an amount of at least about 2.4×1011 vg and in some embodiments wherein the pharmaceutical formulation comprises a rAAV2-hAADC vector concentration of about 5.7×1011 vg/mL. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally further comprises the step of administering a therapeutically effective dose of dopamine-antagonist to the subject such as risperidone. This invention is also directed to methods for treating aromatic L-amino acid decarboxylase (AADC) deficiency, wherein the method optionally comprises providing a pharmaceutical formulation comprising an rAAV2-hAADC vector, and empty capsids.